Schedule 13G ownership disclosure

Fulcrum Therapeutics Inc

Common Stock, par value $0.001 per share · CUSIP: 359616109

Event date: 2024-12-27

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • SUVRETTA CAPITAL MANAGEMENT, LLC

    Shares: 3,404,612.00 · Class: 6.3%

  • Averill Master Fund, Ltd.

    Shares: 3,151,741.00 · Class: 5.8%

  • Aaron Cowen

    Shares: 3,404,612.00 · Class: 6.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000919574-25-000110
Form type
SCHEDULE 13G
Filer
Fulcrum Therapeutics, Inc.
CIK
CIK 1680581
Filed
Jan 06, 2025
Reporting period
Dec 27, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub